Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194869 · ClinicalTrials.gov registry record · Phase 2
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01194869 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 25 participants.
The verdict
NCT01194869, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast tumor and allow you to preserve your breast. Sorafenib is a newer drug that targets blood vessel formation and may help the chemotherapy work better. Additionally, by receiving chemotherapy before surgery, we will be able to determine if your cancer is responsive to chemotherapy.
Interventions
- DRUG Cisplatin
- DRUG Paclitaxel
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194869
The ClinicalTrials.gov registry entry for NCT01194869 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01194869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194869 about?
NCT01194869 is a clinical study titled "Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer". The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast tumor and allow you to preserve your breast. Sorafenib is a newer drug that...
What is the current status of trial NCT01194869?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01194869?
The interventions under investigation include: Cisplatin (DRUG), Paclitaxel (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT01194869?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.